Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicinal mixture for treating arrhythmia

A technology of arrhythmia and drugs, applied in drug combinations, pharmaceutical formulations, cardiovascular system diseases, etc., can solve the problems of reducing the induction rate and duration of AF, prevent the increase of platelet aggregation rate in dogs, and reduce the apoptosis of atrial myocytes , the effect of preventing proteolysis

Inactive Publication Date: 2007-01-17
李为民 +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Preliminary studies by Kumagai et al showed that candesartan may reduce the induction rate and duration of AF by preventing atrial rapid pacing in dogs with SR

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0015] The present invention is described in more detail below in conjunction with accompanying drawing example:

[0016] The two components are uniformly mixed according to the proportion of 5-20 parts of cilazapril and 40-240 parts of valsartan according to the ratio of parts by weight, and the product is packaged.

[0017] The two components are uniformly mixed according to the ratio of cilazapril:valsartan=1:8 in parts by weight, and the product is packaged.

[0018] According to the ratio of 5-20 mg of cilazapril and 40-240 mg of valsartan, the two components are evenly mixed, and packaged to form a product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composite medicine for treating arrhythmia contains cilazapril (5-20 weight portions) and valsartan (40-240 weight portions).

Description

(1) Technical field [0001] What the present invention relates to is a kind of pharmaceutical composition. Specifically, it is a pharmaceutical composition for treating arrhythmia. (2) Background technology [0002] Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Not only the incidence is high and the duration is long, but it can also cause serious complications, such as heart failure and arterial embolism. According to statistics, AF doubles the rate of cardiac mortality, and without proper anticoagulation, the incidence of stroke increases by 5 times, seriously threatening people's health. [0003] AF causes electrical remodeling (ER), structural remodeling (SR) and functional remodeling (Functional remodeling) of atrial myocardium, which contribute to the onset and maintenance of AF, forming a vicious circle. Screening effective drugs that can prevent and treat atrial ER, SR and FR is one of the current research hotspots at home and abroad. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/41A61P9/06A61K31/401
Inventor 李为民李悦张瑞宏
Owner 李为民
PatSnap Eureka logo

PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.

X (Twitter)LinkedInYouTubeSubstack

© 2026 PatSnap. All rights reserved. 

Terms of Service

 | 

Privacy policy

 | 

Modern Slavery Act Transparency Statement